ArriVent Announces Proof-Of-Concept Global Phase 1b Interim Data For Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer; 81.8% ORR By BICR And 63.6% Confirmed ORR By BICR At The 240mg Dose; 46.2% Confirmed ORR In CNS Metastases
Portfolio Pulse from Benzinga Newsdesk
ArriVent BioPharma announced positive interim data from its Phase 1b trial of firmonertinib for EGFR PACC mutant NSCLC, showing high response rates. The company will host a webinar to discuss these findings.
September 09, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ArriVent BioPharma's Phase 1b trial data for firmonertinib in EGFR PACC mutant NSCLC shows promising results with high response rates, potentially boosting investor confidence.
The positive interim data from the Phase 1b trial of firmonertinib indicates strong efficacy in treating EGFR PACC mutant NSCLC, which is likely to enhance investor sentiment and potentially drive the stock price up. The high response rates and the upcoming webinar to discuss these findings further highlight the significance of this development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100